KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Long-Term Debt Repayments (2016 - 2026)

Eli Lilly filings provide 17 years of Long-Term Debt Repayments readings, the most recent being $750.0 million for Q1 2026.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $750.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 764100.0% increase, with the full-year FY2025 number at $778.0 million, up 17.17% from a year prior.
  • Long-Term Debt Repayments hit $750.0 million in Q1 2026 for Eli Lilly, up from -$100000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $849.9 million in Q2 2022 to a low of -$200000.0 in Q4 2024.
  • Median Long-Term Debt Repayments over the past 4 years was $730.0 million (2022), compared with a mean of $514.6 million.
  • The widest YoY moves for Long-Term Debt Repayments: up 50.0% in 2025, down 50.0% in 2025.
  • Eli Lilly's Long-Term Debt Repayments stood at $849.9 million in 2022, then plummeted by 100.02% to -$200000.0 in 2024, then soared by 50.0% to -$100000.0 in 2025, then soared by 750100.0% to $750.0 million in 2026.
  • The last three reported values for Long-Term Debt Repayments were $750.0 million (Q1 2026), -$100000.0 (Q4 2025), and $778.1 million (Q2 2025) per Business Quant data.